Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

374 ARTÍCULOS , VIENDO DEL 166 AL 180

Resveratrol and Amyloid-Beta: Mechanistic Insights

Jia Y, Wang N, Liu X.

Nutrients. 2017 Oct 14;9(10):1122. doi: 10.3390/nu9101122.

Molecular and Cellular Mechanisms of Sporadic Alzheimer's Disease: Studies on Rodent Models in vivo

Gulyaeva NV, Bobkova NV, Kolosova NG, Samokhin AN, Stepanichev MY, Stefanova NA.

Biochemistry (Mosc). 2017 Oct;82(10):1088-1102. doi: 10.1134/S0006297917100029.

Can small molecule inhibitors of glutaminyl cyclase be used as a therapeutic for Alzheimer's disease?

Wu H.

Future Med Chem. 2017 Nov;9(17):1979-1981. doi: 10.4155/fmc-2017-0190. Epub 2017 Oct 27.

Application of Chitosan, Chitooligosaccharide, and Their Derivatives in the Treatment of Alzheimer's Disease

Ouyang QQ, Zhao S, Li SD, Song C.

Mar Drugs. 2017 Nov 7;15(11):322. doi: 10.3390/md15110322.

Editorial: Multi-target Drug Discovery - Part I

Chen JN.

Curr Top Med Chem. 2017;17(27):2997-2999. doi: 10.2174/156802661727171102165810.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8.

A benzothiazole/piperazine derivative with acetylcholinesterase inhibitory activity: Improvement in streptozotocin-induced cognitive deficits in rats

Demir Özkay Ü, Can ÖD, Sağlık BN, Turan N.

Pharmacol Rep. 2017 Dec;69(6):1349-1356. doi: 10.1016/j.pharep.2017.06.009. Epub 2017 Jun 30.

Novel Treatment Strategies Using TiO(2)-Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease

Sharma A, Menon PK, Patnaik R, Muresanu DF, Lafuente JV, Tian ZR, Ozkizilcik A, Castellani RJ, Mössler H, Sharma HS.

Int Rev Neurobiol. 2017;137:123-165. doi: 10.1016/bs.irn.2017.09.002. Epub 2017 Nov 6.

Establishment of induced pluripotent stem cell line (ZZUi010-A) from an Alzheimer's disease patient carrying an APP gene mutation

Wang Z, Zhang P, Wang Y, Shi C, Jing N, Sun H, Yang J, Liu Y, Wen X, Zhang J, Zhang S, Xu Y.

Stem Cell Res. 2017 Dec;25:213-216. doi: 10.1016/j.scr.2017.10.025. Epub 2017 Nov 3.

Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models

Gugliandolo A, Bramanti P, Mazzon E.

Int J Mol Sci. 2017 Nov 23;18(12):2504. doi: 10.3390/ijms18122504.

The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease

Lopez Lopez C, Caputo A, Liu F, Riviere ME, Rouzade-Dominguez ML, Thomas RG, Langbaum JB, Lenz R, Reiman EM, Graf A, Tariot PN.

J Prev Alzheimers Dis. 2017;4(4):242-246. doi: 10.14283/jpad.2017.37.

Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease

Alam J, Blackburn K, Patrick D.

J Prev Alzheimers Dis. 2017;4(4):273-278. doi: 10.14283/jpad.2017.41.

Editorial: Multi-target Drug Discovery - Part II

Chen JN.

Curr Top Med Chem. 2017 Nov 20;17(28):3081-3083. doi: 10.2174/156802661728171120143727.

The past, present, and future of disease-modifying therapies for Alzheimer's disease

Suzuki K, Iwata A, Iwatsubo T.

Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(10):757-771. doi: 10.2183/pjab.93.048.

Rho GTPases as therapeutic targets in Alzheimer's disease

Aguilar BJ, Zhu Y, Lu Q.

Alzheimers Res Ther. 2017 Dec 15;9(1):97. doi: 10.1186/s13195-017-0320-4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias